Stockreport

Cullinan Oncology surges 17% on phase 1/2a non-small cell lung cancer data [Seeking Alpha]

Cullinan Therapeutics, Inc.  (CGEM) 
PDF Cullinan Oncology surges 17% on phase 1/2a non-small cell lung cancer data [Read more]